131.14
price up icon0.19%   0.25
after-market After Hours: 131.00 -0.14 -0.11%
loading
Novo Nordisk Adr stock is traded at $131.14, with a volume of 2.59M. It is up +0.19% in the last 24 hours and up +0.78% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$130.89
Open:
$133.76
24h Volume:
2.59M
Relative Volume:
0.69
Market Cap:
$583.84B
Revenue:
$37.42B
Net Income/Loss:
$13.05B
P/E Ratio:
54.47
EPS:
2.4077
Net Cash Flow:
$9.51B
1W Performance:
-5.76%
1M Performance:
+0.78%
6M Performance:
+5.12%
1Y Performance:
-31.43%
1-Day Range:
Value
$130.57
$134.16
1-Week Range:
Value
$130.53
$138.62
52-Week Range:
Value
$86.96
$201.76

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
69,260
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-08-07
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
Sep 08, 2024

This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth. - The Motley Fool

Sep 08, 2024
pulisher
Sep 07, 2024

Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? - The Motley Fool

Sep 07, 2024
pulisher
Sep 06, 2024

Novo Nordisk ADR [NVO] Stock trading around $130.89 per share: What’s Next? - The DBT News

Sep 06, 2024
pulisher
Sep 06, 2024

This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem - The Motley Fool

Sep 06, 2024
pulisher
Sep 05, 2024

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga

Sep 05, 2024
pulisher
Sep 05, 2024

Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern - Benzinga

Sep 05, 2024
pulisher
Sep 05, 2024

Battle Over Compounded Weight-Loss Medications - Benzinga

Sep 05, 2024
pulisher
Sep 05, 2024

Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - The Motley Fool

Sep 05, 2024
pulisher
Sep 05, 2024

Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors? - The Motley Fool

Sep 05, 2024
pulisher
Sep 04, 2024

BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race - Benzinga

Sep 04, 2024
pulisher
Sep 03, 2024

The Best Biotech Stock to Invest $1,000 in Right Now - The Motley Fool

Sep 03, 2024
pulisher
Sep 03, 2024

2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock - The Motley Fool

Sep 03, 2024
pulisher
Aug 31, 2024

These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now - The Motley Fool

Aug 31, 2024
pulisher
Aug 30, 2024

Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits - Benzinga

Aug 30, 2024
pulisher
Aug 30, 2024

Experts predict Novo Nordisk ADR’s (NVO) current quarter earnings growth rate - US Post News

Aug 30, 2024
pulisher
Aug 30, 2024

How does Novo Nordisk ADR (NVO) change from a tortoise to a hare? - SETE News

Aug 30, 2024
pulisher
Aug 30, 2024

Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients - Benzinga

Aug 30, 2024
pulisher
Aug 30, 2024

Novo Nordisk's Massive GLP-1 Growth Reflects the Firm's Wide Moat in Cardiometabolic Diseases - Morningstar

Aug 30, 2024
pulisher
Aug 30, 2024

This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock - The Motley Fool

Aug 30, 2024
pulisher
Aug 30, 2024

Global GLP-1 Analogues Market Report 2024-2032: Market Expansion Driven by Innovation and Efficacy in Diabetes and Obesity Treatment - GlobeNewswire Inc.

Aug 30, 2024
pulisher
Aug 29, 2024

Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News

Aug 29, 2024
pulisher
Aug 27, 2024

Novo Nordisk ADR (NVO) Stock: From Low to High in 52 Weeks - The InvestChronicle

Aug 27, 2024
pulisher
Aug 27, 2024

Should Novo Nordisk ADR (NYSE: NVO) Investors Be Concerned? - Stocks Register

Aug 27, 2024
pulisher
Aug 27, 2024

Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble? - The Motley Fool

Aug 27, 2024
pulisher
Aug 24, 2024

2 No-Brainer Healthcare Stocks to Buy With $1,000 - The Motley Fool

Aug 24, 2024
pulisher
Aug 23, 2024

Perhaps timely catching Novo Nordisk ADR (NVO) would be a good idea - SETE News

Aug 23, 2024
pulisher
Aug 21, 2024

NVO’s Market Whiplash: 29.57% YTD Rise, 0.57% Rise in 30 Days - The InvestChronicle

Aug 21, 2024
pulisher
Aug 21, 2024

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing - GlobeNewswire Inc.

Aug 21, 2024
pulisher
Aug 21, 2024

Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945? - The Motley Fool

Aug 21, 2024
pulisher
Aug 20, 2024

Why Eli Lilly Topped the Market on Tuesday - The Motley Fool

Aug 20, 2024
pulisher
Aug 20, 2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - GlobeNewswire Inc.

Aug 20, 2024
pulisher
Aug 20, 2024

Hemophilia Market Size to Surpass US$ 23.99 Billion by 2033, The Brainy Insights - GlobeNewswire Inc.

Aug 20, 2024
pulisher
Aug 19, 2024

Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond - The Motley Fool

Aug 19, 2024
pulisher
Aug 18, 2024

Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived - The Motley Fool

Aug 18, 2024
pulisher
Aug 18, 2024

Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years - The Motley Fool

Aug 18, 2024
pulisher
Aug 18, 2024

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year - The Motley Fool

Aug 18, 2024
pulisher
Aug 17, 2024

Is Madrigal Pharmaceuticals Stock a Buy? - The Motley Fool

Aug 17, 2024
pulisher
Aug 17, 2024

3 Fantastic Growth Stocks to Buy in August - The Motley Fool

Aug 17, 2024
pulisher
Aug 17, 2024

Could Viking Therapeutics Become the Next Novo Nordisk? - The Motley Fool

Aug 17, 2024
pulisher
Aug 16, 2024

Is Hims & Hers Health the Best Growth Stock for You? - The Motley Fool

Aug 16, 2024
pulisher
Aug 16, 2024

Are Smart Investors Making the Right Decision? Novo Nordisk ADR (NVO) - SETE News

Aug 16, 2024
pulisher
Aug 16, 2024

Will Novo Nordisk ADR (NVO) beat or miss earnings estimates this quarter? - US Post News

Aug 16, 2024
pulisher
Aug 16, 2024

Novo Nordisk ADR [NVO] moved up 2.34: Why It’s Important - The DBT News

Aug 16, 2024
pulisher
Aug 16, 2024

Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater - The Motley Fool

Aug 16, 2024
pulisher
Aug 15, 2024

Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer) - The Motley Fool

Aug 15, 2024
pulisher
Aug 15, 2024

Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors? - The Motley Fool

Aug 15, 2024
pulisher
Aug 14, 2024

19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris - GlobeNewswire Inc.

Aug 14, 2024
pulisher
Aug 13, 2024

Novo Nordisk ADR: Navigating Market Fluctuations with a 447.00B Market Cap - The InvestChronicle

Aug 13, 2024
pulisher
Aug 13, 2024

Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy? - The Motley Fool

Aug 13, 2024
pulisher
Aug 13, 2024

This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock - The Motley Fool

Aug 13, 2024
pulisher
Aug 12, 2024

Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk - The Motley Fool

Aug 12, 2024

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1,131.50
price down icon 1.66%
$468.00
price down icon 0.12%
$542.00
price down icon 1.18%
$246.78
price down icon 1.87%
$72.89
price down icon 0.75%
Cap:     |  Volume (24h):